Who is sponsoring NCT01508676?

NCT01508676 is sponsored by Massachusetts General Hospital.

What condition does NCT01508676 study?

NCT01508676 studies Neuralgia, Postherpetic Neuralgia, Reflex Sympathetic Dystrophy, Complex Regional Pain Syndrome (CRPS).

What drugs are being tested in NCT01508676?

Interventions: Pennsaid, Placebo (2.3% DMSO solution).

What is the status of NCT01508676?

NCT01508676 is currently COMPLETED.

Last reviewed 2016-12-13 · How we verify

Effects of Pennsaid on Clinical Neuropathic Pain

NCT01508676 NA COMPLETED Results posted

The purpose of this study is to see if the drug Pennsaid (Diclofenac) can help reduce pain felt by people with chronic nerve pain. The drug will be used 2-4 times each day for 2 weeks. The U.S. Food and Drug Administration (FDA) has approved Pennsaid to treat osteoarthritis (bone pain), but the FDA has not approved Pennsaid to treat neuropathic (nerve) pain. The research study will compare Pennsaid to placebo.

Details

Lead sponsor	Massachusetts General Hospital
Phase	NA
Status	COMPLETED
Enrolment	35
Start date	2011-11
Completion	2016-01

Conditions

Neuralgia
Postherpetic Neuralgia
Reflex Sympathetic Dystrophy
Complex Regional Pain Syndrome (CRPS)

Interventions

Pennsaid
Placebo (2.3% DMSO solution)

Primary outcomes

VAS After Treatment — 2 weeks.
Subjects rated their pain using the Visual Analog Scale after a 2 week phase of using pennsaid lotion and after a 2 week phase of using placebo lotion. The Visual Analog Scale is subject reported on a scale of 0-10 with 0 being no pain, and 10 being the worst pain they can imagine. Results reported are an average of reported VAS scores for the 28 subjects who completed both phase I and phase II of the study.

Countries

United States